2023 is shaping up to be a pivotal year for Aldeyra Therapeutics Inc. (ALDX) as it continues to make significant progress in its pipeline of compounds targeting systemic and retinal immune-mediated diseases.
Two of the company's drug candidates - ADX-2191 and Reproxalap - are under FDA review.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.